Addition of Rosiglitazone to Existing Sulfonylurea Treatment in Chinese Patients with Type 2 Diabetes and Exposure to Hepatitis B or C
Author:
Affiliation:
1. Shanghai Huashan Hospital, Shanghai, China
Publisher
Mary Ann Liebert Inc
Subject
Medical Laboratory Technology,Endocrinology,Endocrinology, Diabetes and Metabolism
Link
http://www.liebertpub.com/doi/pdf/10.1089/152091503763816445
Reference18 articles.
1. Section Review: Oncologic, Endocrine & Metabolic: Thiazolidinediones
2. A Novel Antidiabetic Drug, Troglitazone — Reason for Hope and Concern
3. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients
4. Diabetes — a common, growing, serious, costly, and potentially preventable public health problem
5. Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus;BMC Medicine;2020-11-16
2. Standards of medical care for type 2 diabetes in China 2019;Diabetes/Metabolism Research and Reviews;2019-05-29
3. Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis;PLOS ONE;2018-08-27
4. Thiazolidinediones;Meyler's Side Effects of Drugs;2016
5. Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus;American Journal Cardiovascular Drugs;2011-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3